Skip to content Skip to footer
Subscribe Now
Personalis
NEWS

Tempus AI to Acquire Personalis for ~$1.5B

Shots: Tempus AI has entered into a definitive agreement to acquire Personalis, expanding Tempus' capabilities in minimal residual disease (MRD) As per the deal, Personalis shareholders will receive $16.25 per share, valuing the company at an enterprise value of $1.5B, net of Tempus AI’s existing ownership interest; closing expected in late 2026 or early 2027…
12 hours ago

Read more

VIEWPOINTS

Michael Wysocki on Precision Molecular Imaging & PSMA PET Innovation: Blue Earth Diagnostics’ Vision for Personalized Prostate Cancer Care

Shots:  Blue Earth Diagnostics is advancing precision molecular imaging in prostate cancer through its F-18 PET imaging portfolio, with POSLUMA and Axumin designed to improve disease localization, support earlier clinical decision-making, and enhance physician confidence, particularly in patients experiencing biochemical recurrence.  At SNMMI 2026, the company presented new evidence highlighting POSLUMA's strong detection performance at low PSA levels, reduced urinary…
July 13, 2026

Read more

NEWS

Sanyou Biopharmaceutical and Baiyunshan Xihe Partner on AI-Driven Radiopharmaceutical Development

Shots: Sanyou & Baiyunshan Xihe have entered into a strategic collaboration to co-develop novel radiopharmaceuticals & radiodiagnostic products by combining AI-driven drug discovery with nuclear medicine expertise As per the deal, Sanyou Bio will contribute its AI-STAL libraries & AI-Drug Accelerator platform for target molecule discovery, while Baiyunshan Xihe will lead radionuclide production, radiolabeling, preclinical…
July 6, 2026

Read more

NEWS

Guardant Health and Nuvalent Partner on Precision Oncology Diagnostics

Shots: Guardant Health has entered into a multi-year strategic collaboration with Nuvalent to support the development & potential commercialization of Nuvalent’s oncology pipeline using the Guardant Infinity platform The partnership will use Guardant’s tissue & liquid biopsy tests to support Nuvalent’s global clinical studies & evaluate companion diagnostic development for Nuvalent’s investigational cancer therapies The…
May 1, 2026

Read more

VIEWPOINTS

Turning Genome Data into Clinical Insight: Jehee Suh of Inocras on AI-Driven Genomics 

Shots:  Inocras is advancing the clinical adoption of whole-genome sequencing (WGS) by transforming it from a research tool into a standardized diagnostic workflow, refining its algorithms through thousands of real-world patient cases to deliver actionable genomic insights in routine care.  Through platforms such as CancerVision, RareVision, and MRDVision, the company integrates deep genomic analytics, AI-driven bioinformatics, and clinical services like genetic counseling and…
March 31, 2026

Read more

THOUGHTSPOT

Whole-genome sequencing meets real-world outcomes: what 1,364 breast cancer genomes reveal about treatment response

Author: Jehee Suh, CEO, Inocras Breast cancer is not one disease. It’s a set of biologically distinct malignancies that differ by subtype, clinical behavior, and most importantly, how patients respond to therapy. Over the past two decades, oncology has made real progress by aligning treatment to a handful of established biomarkers (ER/PR, HER2, BRCA1/2). Despite…
March 3, 2026

Read more

VIEWPOINTS

Pictor Labs at SITC 2025: Megan Rothney on How ClearStain Is Transforming Molecular Sequencing and Precision Oncology

Shots:  ClearStain debuted at SITC 2025 as a workflow-changing innovation, delivering high-quality virtual H&E images from unstained slides to improve tumor identification, reduce sequencing failures, preserve tissue, and accelerate molecular and precision oncology workflows  By enabling direct visualization and annotation of the exact tissue destined for sequencing, ClearStain helps pathologists and molecular labs maximize tumor purity, minimize impurities,…
January 19, 2026

Read more

NEWS

D3 Bio Receives the US FDA IND Clearance to Initiate P-I trial of D3S-003 & P-II Combination Study of Elisrasib (D3S-001) with D3S-002

Shots: FDA has granted IND clearance to initiate D3S-003 a P-I, and a P-II combination study of D3S-001 (elisrasib), a next-gen KRAS G12C inhibitor, with D3S-002, an oral ERK1/2 inhibitor The P-II trial will evaluate the D3S-001 + D3S-002 combination in KRAS G12C–mutant NSCLC patients who have progressed on prior KRAS G12C therapies to assess…
January 19, 2026

Read more

NEWS

Gilead Sciences to Acquire Repare Therapeutics’ Polθ ATPase Inhibitor RP-3467 for ~$30M

Shots: Repare Therapeutics has entered into a definitive asset purchase agreement with Gilead Sciences for the acquisition of Repare's RP-3467, a polymerase theta (Polθ) ATPase inhibitor, strengthening Gilead’s precision oncology pipeline Under the Agreement, Repare will receive up to $30M in total consideration, including $25M upfront (subject to customary adjustments) and an additional $5M upon…
December 25, 2025

Read more

NEWS

Bayer Enters a ~$1.3B Deal with Kumquat Biosciences to Develop and Commercialize a KRAS G12D Inhibitor

Shots: Bayer has entered into an exclusive global license agreement & collaboration with Kumquat Biosciences to develop and commercialize its KRAS G12D inhibitor Kumquat will initiate & complete the P-Ia study following FDA’s IND clearance in Jul 2025, while Bayer handles further development & commercialization, with Kumquat holding an exclusive option to negotiate US profit-loss…
August 13, 2025

Read more

Load more